An increasing number of studies based on clinical observations and experimental mouse models highlight the opportunities for targeting the IL-22-IL-22R axis as novel, promising therapeutic strategies for NAFLD. Here, IL22RA1 is linked to metabolic dysfunction-associated steatotic liver disease.